My tirzepatide plateau with PCOS: what should be checked first?

Lena is thirty-eight. She has carried a PCOS diagnosis since her twenties, and for most of the past year she has filled tirzepatide through a telehealth prescriber she has never met on video. The first months moved the scale. Then it stopped, and the next message in her inbox offered the next dose. Nobody asked what had changed, and nobody ordered a lab. Lena is a composite, built from situations like hers, and she is not a real patient. This piece follows her first three months with GoodLife Health: what we would check, why we would check it, and what it would cost.

If you searched for something close to "tirzepatide plateau with PCOS", you are probably asking two questions at once. Why did it stop working? And is a membership like ours only for weight loss, or does it also cover the rest of what PCOS brings? The second question has a short answer, which is no. The first has a longer one, and it starts with a blood draw rather than a higher dose.

A dose that kept rising, and a question nobody asked

You may recognize the shape of Lena's PCOS history. Her cycles were irregular for years before anyone gave the pattern a name. Jawline acne, bloating and a crash after meals came and went. One clinician offered her the pill, which regulated the bleed and told her nothing about why it had been irregular. Another suggested fewer carbs. Nobody ever drew her fasting insulin, so nobody could say how much of her picture was insulin and how much was something else.

When GLP-1 medication became something she could request through an online form, she filled one in. For a while it looked like the first thing that had worked. Then the plateau arrived quietly: two months on the same number, then three. She mentioned it in a check-in form, along with the side effects that had never fully settled, and the reply was a new dose and a new shipping date. Each step up arrived the same way. Nobody asked about her cycle, her sleep or the crash after meals. Nobody explained that a stall can have more than one cause, or that some of those causes show up in blood work and nowhere on a scale.

Lena has not been careless. She followed the instructions she was given. What she has not had is a clinician whose job is to find the reason before choosing the next step. If your own story runs along these lines, your frustration is reasonable. You were handed a medication with a strong evidence base, and no one was assigned to find out why it stopped working for you.

Underneath that sits the question this piece is named for. If the weight has stalled, does a membership make sense at all, or is it one more weight-loss program with a monthly fee? Lena would want that answer from someone with nothing to gain from the next dose.

What a plateau can mean, and what nobody can know in advance

GoodLife Health starts from a plain observation about the body: weight, hormones, thyroid, blood sugar and insulin, lipids and inflammation form one connected system. Insulin resistance drives weight gain, visceral fat disrupts hormones, and disrupted hormones stall metabolism. When one provider manages one piece, the other pieces keep moving whether anyone is watching or not. Our definitive guide to cardiometabolic optimization sets out the whole model. For Lena, the sentence that matters most in it is this one: hormonal health is the axis most weight-loss platforms skip entirely, and the reason so many protocols stall.

With PCOS, the questions that come with the diagnosis already span two parts of that system: insulin on the metabolic side, and the androgens and the cycle on the hormonal side. Fasting insulin, thyroid and the androgens, read together, are where the answer begins. A higher dose addresses one possible reason for a plateau. It cannot address the others, because nothing about them was measured.

There is a lot we do not know. Before the first panel, we do not know why Lena's weight stopped moving. The results might point somewhere clear. They might show nothing that explains the stall. If so, the honest answer is that we keep looking with her, quarter by quarter, rather than reaching for the next step by default. What we can describe is the order of operations: test first, then decide. The dose may stay where it is, rise, fall or change to a different medication. That is the clinician's decision, made from her numbers and not from a titration calendar.

The field is moving toward this order, and the numbers explain why. According to the CDC's National Diabetes Statistics Report, more than 130 million American adults live with diabetes or prediabetes. NHANES data from 2009 to 2016 found that only 12% of U.S. adults were metabolically healthy. An eight-minute annual visit was never built to follow a slow, whole-system condition at that scale. Labs-first care reads fasting insulin and HbA1c where a single glucose value used to stand, and it puts ApoB and Lp(a) beside the standard cholesterol panel. It reads results against optimal ranges rather than population reference ranges, because a population range describes many people and the patient in the room is one. A panel drawn every quarter turns a prescription from a guess into a feedback loop, which annual blood work cannot do.

Lena already has a prescriber, and she may wonder why she would need anyone else. A prescriber can write the next prescription. A clinician who stays reads the next panel against the last one and explains each decision. Your current prescriber may already draw fasting insulin, thyroid and the androgens, read them with you and tell you why each dose was chosen. If so, you may not need us. If you have only ever had the prescription, that is the gap this membership was built to fill.

It is also fair to ask how anyone who prescribes is paid. Most telehealth platforms earn more when you are prescribed more, through margin on the molecule or an upcharge as the dose rises. We cannot know why Lena's prescriber chose each step, and we will not guess. We can tell you how we are paid. The membership fee is the same whatever medication is indicated and whatever the dose, and GoodLife Health sets nothing, sees nothing and takes nothing on medication. A higher dose earns us nothing, and a lower one costs us nothing.

One more fact belongs here, because it changes what happens next. Tirzepatide is sold under the brand names Zepbound and Mounjaro, both FDA-approved. If the vials Lena has been filling are a compounded copy, she should know the record before she decides anything. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss, and the manufacturers have gone to court over compounded copies. Dosing and additive practices among compounders have also been reported. Responsibility for what is in a vial, and for the dose, sits with the prescribing clinician's license. GoodLife Health prescribes branded, FDA-approved medication only and never a compounded GLP-1, so a move from a compounded copy would be a conversation for her first visit.

Lena's first three months with GoodLife Health

Before anything starts: the check, the intake and the review

Lena begins with the eligibility check, then the intake, then checkout, where $598 covers her first two months. A clinician then reviews her case, because not everyone is accepted. If the clinician cannot accept her into care, the $598 is refunded in full. Once she is accepted, the first two months are non-refundable. Any medication a pharmacy bills her follows that pharmacy's own return and refund policy.

She brings what she has: the dates of each dose step, the side effects she reported, whatever labs she can find from earlier visits, and her PCOS history, including the pill she was offered. Together these become the starting record a clinician reads before the first draw.

Month one: the first panel

The first cardiometabolic panel is the foundation for everything that follows. It covers four groups of markers, and each group answers its own question.

Every result goes into Lena's hands. She sees the numbers the clinician sees, read against optimal ranges rather than the population reference range printed on the report. Drawn together, the markers explain each other. When one clinician reads them all, an insulin result means more beside the androgens, and a thyroid result means more beside the weight history.

Month two: reading it together and deciding about the dose

Lena and her clinician go through the panel on a video visit. Between visits she can message the care team, so the side effects she reported, and any new ones, now reach someone who reads them.

The dose decision comes from the panel. Depending on what it shows, the clinician might hold the dose, adjust it or move to a different branded medication. Where the results indicate it, hormone therapy or thyroid medication can be part of the plan, and any FDA-approved medication the clinician judges indicated can be prescribed to the pharmacy Lena chooses. Nothing is promised in advance, and nothing is added because a plan has a slot for it. Our guide to hormone therapy at pharmacy cost shows what those medications cost when no one in the chain takes a margin.

Month three: the second panel

Around the end of month three, Lena's second panel is drawn, the second of four a year. This time the comparison is with her own first panel. If her insulin markers moved, the clinician can see by how much. If the weight starts moving again, she will have a better idea of why. If it does not, the next decision is made with two sets of numbers instead of none. We cannot tell you which of these Lena's quarter will bring, but each one leaves her with more information than the next dose step would have.

After the first two months, the membership continues month to month at $299. The clinician who read the first panel reads the second, and the one after that.

What it costs, and what it does not do

The membership is $299 a month, and a year of it is $3,588. It covers clinicians licensed in all fifty states, four cardiometabolic lab panels a year, every result in the patient's hands, asynchronous messaging with the care team and video visits. The fee is generally eligible for HSA or FSA pre-tax dollars.

Medication is a separate number, and we never set it. Suppose Lena's clinician prescribes branded tirzepatide as Zepbound. As of September 2026, the published self-pay price for vials through LillyDirect was $299 to $449 a month, depending on dose. Her own pharmacy may price it differently, and she pays what that pharmacy charges. Whether her insurance covers it is between Lena, her plan and her pharmacy. Prior authorization is the pharmacy's process. We do not run it, speed it up or win it, and we never promise coverage.

That answers a fair objection: why pay a membership when the drug is the expensive part? The drug may well be the larger number. The membership pays for the reasoning behind the dose, and because we take nothing on the drug, that reasoning has no incentive to lean one way. The same test applies to any cheaper online prescription. A prescription fee tells you a price, and it tells you nothing about whether anyone's income rises with your dose. Ask that question of every prescriber, including us. Our answer is that it does not.

The membership pairs with insurance and does not replace it. Keep your insurance for the hospital and the emergency. What the membership replaces is the primary-care relationship.

So, is this only for weight loss?

No. The membership is primary care for the cardiometabolic system, delivered by a clinician who stays: diagnosis first, then treatment, then the long haul. For Lena, weight is one of the markers on her panel, alongside insulin, thyroid, the androgens, lipids and ApoB. Her cycle, the crash after meals and the questions PCOS raised in her twenties all belong to the same conversation, and they stay in it after the scale stops being the main topic.

Whether or not you join, here is what you can do this week.

• Check the label on your medication, and write down whether it is branded Zepbound, Mounjaro or a compounded preparation.
• Write out your dose history with dates: each step, when you reported the plateau, and the side effects you mentioned.
• Ask your current prescriber whether fasting insulin, HbA1c, a thyroid panel and the androgens have ever been drawn, and ask for copies of any results.
• Ask how your prescriber is paid, and whether the fee changes as your dose rises.

If the answers satisfy you, you have what you need. If they do not, you now know exactly what is missing.

Who this is not for

This membership is not for someone who wants a refill at the lowest possible fee with no one asking questions. It is not for anyone who wants compounded tirzepatide, because we will not prescribe it. It is not for someone looking for a guaranteed number on the scale; we cannot promise weight loss, remission or a cure, and we will not imply one. It does not replace health insurance. Care is available only to residents of the fifty states. And it is not for someone whose current clinician already tests first, reads every result with them and explains each dose. If that describes your care, stay where you are.

For Lena, and for anyone whose plateau was answered only with a higher dose, here is the offer in full. GoodLife Health costs $299 a month. You pay $598 at sign-up for the first two months, and the membership is month to month after that. If a clinician cannot accept you into care, the $598 is refunded in full. Once you are accepted, the first two months are non-refundable, and medication billed by a pharmacy follows that pharmacy's own refund policy. The fee buys a quarterly panel, a clinician who stays and reads every result with you, and medication prescribed to your pharmacy at that pharmacy's price, with nothing taken on it. In return you get the diagnosis that an online form and a dose schedule never produced, your markers followed over time, and no repeat of the eight-minute visit. The difference is that we test first, treat second, and sell neither the drug nor the dose. The time to start is before the next escalation email, so that one panel can inform the next step up, or show you do not need it.

Related Reading

• Cardiometabolic Optimization: The Definitive Guide
• Bioidentical Hormone Therapy at Pharmacy Cost: The Real Numbers

References

1. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
2. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss